These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33459227)

  • 21. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.
    Baldelli S; Merlini S; Perico N; Nicastri A; Cortinovis M; Gotti E; Remuzzi G; Cattaneo D
    Pharmacogenomics; 2007 Sep; 8(9):1127-41. PubMed ID: 17924828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study.
    Li L; Li CJ; Zheng L; Zhang YJ; Jiang HX; Si-Tu B; Li ZH
    Eur J Clin Pharmacol; 2011 Aug; 67(8):787-95. PubMed ID: 21331500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.
    Provenzani A; Santeusanio A; Mathis E; Notarbartolo M; Labbozzetta M; Poma P; Provenzani A; Polidori C; Vizzini G; Polidori P; D'Alessandro N
    World J Gastroenterol; 2013 Dec; 19(48):9156-73. PubMed ID: 24409044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients.
    Miura M; Satoh S; Inoue K; Kagaya H; Saito M; Inoue T; Habuchi T; Suzuki T
    Steroids; 2008 Oct; 73(11):1052-9. PubMed ID: 18502461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
    Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
    Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
    Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
    Vannaprasaht S; Reungjui S; Supanya D; Sirivongs D; Pongskul C; Avihingsanon Y; Tassaneeyakul W
    Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphisms in CYP3A5*3 and MDR1, and haplotype modulate response to plasma levels of tacrolimus in Chinese renal transplant patients.
    Wu P; Ni X; Wang M; Xu X; Luo G; Jiang Y
    Ann Transplant; 2011; 16(1):54-60. PubMed ID: 21436775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients.
    Kim IW; Moon YJ; Ji E; Kim KI; Han N; Kim SJ; Shin WG; Ha J; Yoon JH; Lee HS; Oh JM
    Eur J Clin Pharmacol; 2012 May; 68(5):657-69. PubMed ID: 22183771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of pharmacogenetics to optimize immunosuppressive therapy.
    Macphee IA
    Ther Drug Monit; 2010 Jun; 32(3):261-4. PubMed ID: 20431509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil.
    Cilião HL; Camargo-Godoy RBO; Souza MF; Zanuto A; Delfino VDA; Cólus IMS
    Mutat Res Genet Toxicol Environ Mutagen; 2018 Dec; 836(Pt B):97-102. PubMed ID: 30442353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients.
    García M; Macías RM; Cubero JJ; Benítez J; Caravaca F; Gervasini G
    Eur J Clin Pharmacol; 2013 Mar; 69(3):385-93. PubMed ID: 22886152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.
    Turolo S; Tirelli AS; Ferraresso M; Ghio L; Belingheri M; Groppali E; Torresani E; Edefonti A
    Pharmacol Rep; 2010; 62(6):1159-69. PubMed ID: 21273673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.
    Zhao W; Elie V; Roussey G; Brochard K; Niaudet P; Leroy V; Loirat C; Cochat P; Cloarec S; André JL; Garaix F; Bensman A; Fakhoury M; Jacqz-Aigrain E
    Clin Pharmacol Ther; 2009 Dec; 86(6):609-18. PubMed ID: 19865079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
    Díaz-Molina B; Tavira B; Lambert JL; Bernardo MJ; Alvarez V; Coto E
    Transplant Proc; 2012 Nov; 44(9):2635-8. PubMed ID: 23146479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.